Srpski arhiv za celokupno lekarstvo 2012-01-01

[Atrial fibrillation after coronary artery bypass surgery: possibilities of prevention].

Biljana Obrenović-Kirćanski, Bojana Orbović, Mile Vraneš, Biljana Parapid, Nataša Kovačević-Kostić, Miloš Velinović, Stana Ristić

Index: Srp. Arh. Celok. Lek. 140(7-8) , 521-7, (2012)

Full Text: HTML

Abstract

Atrial fibrillation occurs as a frequent complication after cardiac interventions. It can be found in 5% of all surgical patients, and it is far more common in cardiac (10% - 65% of patients) than in non-cardiac procedures. In a number of patients it remains asymptomatic, but may be accompanied by very severe symptoms of hypotension, heart failure, syncope, systemic or pulmonary embolism, perioperative myocardial infarction, cerebrovascular insult and increased operative mortality. Patients whose postoperative course is complicated by atrial fibrillation require longer hospitalization. Possible predisposing factors of this arrhythmia are numerous and are associated with surgery, extensive coronary heart disease and revascularization, and preoperative diseases. According to the recommendations of the European Society of Cardiology orally applied beta-blocker, amiodarone and sotalol can be used for prophylaxis of atrial fibrillation. Following the recommendations, treatment of postoperative atrial fibrillation should include beta-blockers, amiodarone, and in patients with heart failure and left ventricular dysfunction, digoxin. Due to the increased risk of stroke, an anticoagulant protection is necessary. Many studies have been conducted with results supporting the prophylactic use of amiodarone and beta-blockers, while the treatment with new agents such as magnesium, statins, omega-3 fatty acids and inhibitors of the renin-angiotensin-aldosterone system is still being investigated.


Related Compounds

Related Articles:

A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.

2010-12-01

[Assay Drug Dev. Technol. 8 , 714-26, (2010)]

Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women.

2013-12-01

[Heart 99(23) , 1755-60, (2013)]

Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.

2015-02-01

[Am. J. Cardiol. 115(3) , 316-22, (2015)]

In vitro model for assessing arrhythmogenic properties of drugs based on high-resolution impedance measurements.

2012-01-01

[Cell Physiol. Biochem. 29(5-6) , 819-32, (2012)]

Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers.

2012-04-20

[Life Sci. 90(15-16) , 607-11, (2012)]

More Articles...